UroGen Pharma (URGN) Current Assets (2016 - 2026)
UroGen Pharma's (URGN) quarterly Current Assets came in at $237.5 million in Q1 2026, little changed YoY from $237.2 million in Q1 2025, and up 27.65% on a QoQ basis from $186.0 million in Q4 2025.
UroGen Pharma (URGN) Current Assets (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Current Assets data on file, last reported at $237.5 million in Q1 2026.
- Quarterly Current Assets changed 0.12% year-over-year to $237.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $237.5 million (changed 0.12% YoY) and the FY2025 annual result came in at $186.0 million, down 32.63% from the prior year.
- Current Assets improved to $237.5 million in Q1 2026, from $186.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $295.1 million in Q3 2024 to a low of $81.3 million in Q2 2023.
- A 5-year average of $185.4 million and a median of $182.1 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets surged 242.99% — and 2025, when it slumped 42.88%.
- Tracing URGN's Current Assets over 5 years: stood at $128.9 million in 2022, then soared by 31.25% to $169.2 million in 2023, then jumped by 63.21% to $276.1 million in 2024, then sank by 32.63% to $186.0 million in 2025, then rose by 27.65% to $237.5 million in 2026.
- The last three Current Assets figures came in at $237.5 million (Q1 2026), $186.0 million (Q4 2025), and $168.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 235.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 235.43 Mn |
| Mar 31, 2026 | 237.46 Mn |
| Dec 31, 2025 | 186.02 Mn |
| Sep 30, 2025 | 168.55 Mn |
| Jun 30, 2025 | 196.87 Mn |
| Mar 31, 2025 | 237.18 Mn |
| Dec 31, 2024 | 276.14 Mn |
| Sep 30, 2024 | 295.10 Mn |
| Jun 30, 2024 | 278.97 Mn |
| Mar 31, 2024 | 196.76 Mn |
| Dec 31, 2023 | 169.19 Mn |
| Sep 30, 2023 | 182.12 Mn |
| Jun 30, 2023 | 81.33 Mn |
| Mar 31, 2023 | 95.97 Mn |
| Dec 31, 2022 | 128.91 Mn |
| Sep 30, 2022 | 121.59 Mn |
| Jun 30, 2022 | 139.62 Mn |
| Mar 31, 2022 | 160.52 Mn |
| Dec 31, 2021 | 114.39 Mn |
| Sep 30, 2021 | 125.14 Mn |